21:48 , Jun 6, 2019 |  BC Innovations  |  Translation in Brief

CRISPR pioneer Zhang describes new technique to insert genes

Feng Zhang's latest study brings the gene editing field one step closer to correcting and replacing, rather than just disrupting, target genes. The challenge now will be translating the technique from prokaryotic cells to eukaryotic...
21:53 , May 31, 2019 |  BC Extra  |  Company News

Bio Palette deal expands Beam's base editing toolbox, Japan strategy

Genome editing companies Beam and Bio Palette announced a cross-licensing deal Friday that grants each biotech access to the other's base editing technologies. The deal also signals Beam is looking for additional opportunities in Japan,...
21:58 , May 28, 2019 |  BC Innovations  |  Translation in Brief

Liu’s new strategy could make gene editing insertions more precise

The latest study from CRISPR veteran David Liu describes a new tweak to the gene editing machinery that could better position it to correct, rather than just disrupt, gene targets. Using CRISPR to disrupt a...
00:01 , May 23, 2019 |  BioCentury  |  Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series A funding led by existing investor Arch Venture Partners, which the San Diego company plans to use to bring...
19:17 , May 15, 2019 |  BC Innovations  |  Translation in Brief

Optimizing base editors to reduce RNA edits

Two Beam co-founders, Keith Joung and David Liu, have separately optimized CRISPR-guided base editors to reduce off-target RNA editing, which, along with unwanted DNA edits, is an emerging problem for the gene engineering tools. Beam...
23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Beam raises $135M series B

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
12:11 , Mar 6, 2019 |  BioCentury  |  Finance

Beam broadens base with $135M B round

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...